Heron Therapeutics, Inc. (HRTX) — Financial statements
Income statement, balance sheet, and cash flow for Heron Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 155↑7.4% | 144↑13.6% | 127↑18.0% | 108↑24.7% | 86 | |
| Cost of Revenue | 41↑7.0% | 39↓40.6% | 65↑18.6% | 55↑19.2% | 46 | |
| Gross Profit | 114↑7.5% | 106↑70.6% | 62↑17.3% | 53↑30.9% | 40 | |
| Operating Expenses | ||||||
| R&D Expenses | 12↓25.5% | 17↓57.4% | 39↓52.7% | 83↓36.8% | 131 | |
| General & Administrative Expenses | 55↑2.3% | 53↓8.7% | 58↓6.0% | 62↑55.0% | 40 | |
| Selling & Marketing Expenses | 49↑4.2% | 47↓23.2% | 61↓25.7% | 83↓5.4% | 87 | |
| SG&A Expenses | 104↑3.2% | 100↓16.1% | 120↓17.2% | 145↑13.7% | 127 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 14 | 0.00 | 0.00 | |
| Operating Expenses | 116↓0.9% | 117↓32.1% | 173↓24.1% | 227↓11.9% | 258 | |
| Total Costs & Expenses | 157↑1.0% | 156↓34.4% | 238↓15.8% | 282↓7.2% | 304 | |
| Operating Results | ||||||
| Operating Income | -3↑78.0% | -12↑89.6% | -111↑36.7% | -175↑19.8% | -218 | |
| Depreciation & Amortization | 2↓7.1% | 2↓14.0% | 3↑0.3% | 3↓4.4% | 3 | |
| EBITDA | -18↓253.7% | -5↑95.1% | -104↑41.2% | -177↑17.9% | -215 | |
| EBIT | -20↓167.6% | -8↑92.9% | -107↑40.6% | -180↑17.7% | -218 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↑100.0% | -2↓392.5% | -0.50↑39.7% | -0.84↑57.7% | -2 | |
| Interest Income | 0.00↓100.0% | 4↑5.5% | 3↑105.4% | 2↑278.3% | 0.43 | |
| Interest Expense | 0.00↓100.0% | 6↑55.9% | 4↑56.3% | 2↑2.7% | 2 | |
| Non-Operating Income | 18↑543.6% | -4↓1.4% | -4↓180.2% | 5↑999.3% | 0.45 | |
| Other Income / Expenses | -18↓760.5% | -2↓3764.3% | 0.06↑100.8% | -7↓158.0% | -3 | |
| Income Before Tax | -20↓48.7% | -14↑87.7% | -111↑39.3% | -182↑17.5% | -221 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -20↓48.7% | -14↑87.7% | -111↑39.3% | -182↑17.5% | -221 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -20↓48.7% | -14↑87.7% | -111↑39.3% | -182↑17.5% | -221 | |
| Bottom-Line Net Income | -20↓48.7% | -14↑87.7% | -111↑39.3% | -182↑17.5% | -221 | |
| EPS (Basic) | -0.12↓34.7% | -0.09↑88.9% | -0.80↑52.1% | -1.67↑25.4% | -2.24 | |
| EPS (Diluted) | -0.12↓34.7% | -0.09↑88.9% | -0.80↑52.1% | -1.67↑25.4% | -2.24 | |
| Weighted Average Shares | 167↑9.4% | 152↑10.4% | 138↑26.7% | 109↑10.7% | 98 | |
| Weighted Average Diluted Shares | 167↑9.4% | 152↑10.4% | 138↑26.7% | 109↑10.7% | 98 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.